02.02.10
Dalton Pharma Services has successfully completed its Health Canada audit and has received a 'compliant' rating for its GMP manufacturing facility. The Establishment License enables the company to continue to manufacture, test and ship sterile commercial products for its clients. Dalton's solid dose manufacturing suites were also found to be compliant for formulation, granulation and encapsulation of drug products.
In separate audits, the company was also found to be compliant with GMP API manufacturing, sterile filling and testing standards for pharmaceutical products in the EU.
"These successful inspections will allow us to continue to execute on our vision to accelerate drug development for our clients' pharmaceutical products globally. Dalton's ability to carry out commercial manufacture of sterile, solid dose pharmaceuticals and API provides integrated drug development and manufacturing solutions. Dalton's reputation for its ability to complete complex drug manufacturing projects in GMP compliant facilities enhances our clients' success in bringing the medicines of the future to the market," said Peter Pekos, president and chief executive officer.
In separate audits, the company was also found to be compliant with GMP API manufacturing, sterile filling and testing standards for pharmaceutical products in the EU.
"These successful inspections will allow us to continue to execute on our vision to accelerate drug development for our clients' pharmaceutical products globally. Dalton's ability to carry out commercial manufacture of sterile, solid dose pharmaceuticals and API provides integrated drug development and manufacturing solutions. Dalton's reputation for its ability to complete complex drug manufacturing projects in GMP compliant facilities enhances our clients' success in bringing the medicines of the future to the market," said Peter Pekos, president and chief executive officer.